Strategic vaccine platforms Abera’s proprietary mucosal vaccine platforms, including OMV-based BERA, enable rapid development of multivalent, multi-stage vaccines for oral and nasal administration, presenting a compelling opportunity to offer agile vaccine development services and partnerships for outbreak readiness.

Clinical collaboration Active plans for first-in-human trials in the Netherlands with Radboud UMC and GMP-produced clinical material for Ab-01.12 create a pathway for CRO, regulatory, and manufacturing support opportunities, as well as potential co-development or licensing discussions.

Outbreak readiness Ongoing CEPI collaboration on nasal influenza vaccine and a focus on rapid, intranasal vaccines positions Abera as a partner for pandemic preparedness programs, government contracts, and funding-supported vaccine initiatives.

Manufacturing agility Ambition to manufacture OMV vaccines within 14-30 days highlights potential to offer flexible, scalable manufacturing services, tech-transfer partnerships, and faster time-to-market for collaboration partners and clients with tight timelines.

Strategic partnerships Recent collaborations with Orexo for powder vaccines and the multi-institutional Radboud UMC engagement indicate a strong openness to co-development, licensure, and supply agreements, enabling sales plays around joint ventures and contract manufacturing.